Wasdell Group expands portfolio with Honeywood acquisition

AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia

The Wasdell Group (Wasdell), a leading outsourcing partner for companies in the pharmaceutical industry, has announced its acquisition of Honeywood Limited, a specialist manufacturer and packager located in Northampton, UK.

The acquisition will strengthen and expand Wasdell’s manufacturing and packaging capacity in the UK to support the company’s growing client portfolio. The acquired site will also help to maintain the group’s additional portfolio of nutraceutical clients.

Honeywood has operated as a contract manufacturer to the pharmaceutical and healthcare industries for over 20 years.

This news follows the recent announcement about the group’s European headquarters in Dundalk, Ireland, a custom-built state-of-the-art facility that is set to open its doors later this month.

Commenting on the announcement, Vincent Dunne, CEO of The Wasdell Group, said: “Expanding our current offering is the latest step in our ongoing strategic growth plans to meet rising demand for outsourced pharmaceutical services.

“By increasing our capacity and service offerings here in the UK, we will be able to better service our growing client base in the US as they look to Wasdell to provide a fully outsourced supply chain for their products within Europe.”

Martin Tedham, Chairman of the Wasdell Group, added: “Customers will benefit from expanded services, capacity and continuity. Honeywood’s operations will easily integrate into our current operations, and we are looking forward to collaborating with the current owners and staff moving forward.”

Honeywood Limited was advised on this transaction by Wilson Browne Solicitors.